CA2427470A1 - Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function - Google Patents
Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function Download PDFInfo
- Publication number
- CA2427470A1 CA2427470A1 CA002427470A CA2427470A CA2427470A1 CA 2427470 A1 CA2427470 A1 CA 2427470A1 CA 002427470 A CA002427470 A CA 002427470A CA 2427470 A CA2427470 A CA 2427470A CA 2427470 A1 CA2427470 A1 CA 2427470A1
- Authority
- CA
- Canada
- Prior art keywords
- vitamin
- cognitive function
- day
- deterioration
- carnitine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A composition comprising an antioxidant or mixture thereof in quantities sufficient to prevent, or inhibit, or reverse deterioration of cognitive function.
Description
COMPOSITION AND METHOD
Background Of The Invention As humans age their mental faculties appear to lessen. This applies to humans in general and is not related to specific conditions such as Alzheimer's and other known-specific disease conditions affecting mental capacity. Memory is not as good as it once was.
Learning certain tasks can take a longer time. These types of mental changes are some times associated with or referred to as "old age".
Fairly recently this general area is known as cognitive function deterioration and in more generic terms as diminished mental capacity.
This deterioration of cognitive function in older humans can now be prevented, inhibited or treated with specific components.
These components can be administered in the diet or taken separately orally.
Summary Of The Invention In accordance with the invention there is a composition comprising an antioxidant or mixture thereof quantities sufficient to a. prevent or b. inhibit, or c. reverse deterioration of cognitive function, A further aspect is a method of preventing, inhibiting or reversing deterioration of cognitive function through the administration of this composition.
Detailed Description Of The Invention Humans can start having deterioration in cognitive function as early as about 50 but generally it can become noticeable at 60, or 70 years of age.
As used in this application, the components) that accomplish this are an antioxidant or mixture thereof. An antioxidant is a material that quenches a free radical. Examples of such materials are beta-carotene, selenium, coenzyme Q 10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha-lipoic acid, 1-carnitine and the like. Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like Vitamin E acetate, succinate, palmitate, and the like. The alpha form is preferable but beta, gamma and delta forms can be included. The d form is preferable but racemic mixtures are acceptable. The forms and derivatives will function in a Vitamin E like activity after ingestion. . Vitamin C can be administered as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like which will function in a vitamin C like activity after ingesting by the human.
They can be in any form such as liquid, semisolid, solid and heat stable form. Alpha-lipoic acid can be administered as alpha lipoic acid or as a lipoate derivative as in US Patent 5,621,117, racemic mixtures, salts, esters or amides thereof. L-carnitine and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinates, as well as acetylated carnitine, and the like can be used.
The quantities administered to the human are calculated as the active material, per se, that is measured as specific material. The minimum amounts employed should not bring about toxicity. Vitamin E minimum is about 50 or 100 or 150 mg/ day. Generally, no more than about 2,000 or desirably about 1,000 or about 750 mg/day can be employed. Vitamin C minimum quantities are generally about 150, about 200 or about 250 mg/day. Maximums generally do not exceed about 1,000 mg/day but can be lower, for example, about 900 or about 750 mg/ day. Alpha lipoic acid can be administered up to about or 20 mg/ kg body weight/ day. Minimums are about .5 or 1 mg/ kg body weight/ day. L-carnitine is administered in the same manner as alpha lipoic acid. Alpha lipoic acid and 1-carnitine can be administered at much higher levels but there is no substantially different efficacy observed.
Additional antioxidants and their quantities are given in mg/kg body weight/ day numbers.
Beta-carotene at least about 0.02 mg/kg body weight/day 1-15 ppm can be employed.
Selenium at about 0.02 mg/ kg body weight/ day up to 5 ppm can be employed.
Lutein at least about 5 ppm mg/kg body weight/day can be employed.
Tocotrienols at least about 0.5 mg/ kg 'body weight/ day can be employed.
Coenzyme Q 10 at least about 0.5 mg/ kg body weight/ day can be employed.
S-adenosylmethionine at least about 1.0 mg/ kg body weight/ day can be employed.
Taurine at least about 10 mg/kg body weight/day can be employed.
Soy isoflavones at least about 0.5 mg/kg body weight/day can. be used.
N-acetylcysteine at least about 1.0 mg/ kg/ body weight/ day can be used.
Glutathione at least about 1.0 g/kg body weight/day can be used.
Ginkgo Biloba at least 1.0 mg/kg body weight/day can be used.
The quantities can be administered in a typical "one a day"
dosage similar to a vitamin. It can be administered in tablet, capsule, caplet for example, or in a liquid carrier form all for ingestion by the human. Additionally, the daily dosage can be broken down into two, three, or four dosage unit forms for convenience or other reasons.
Additionally, it can be administered in a food such as snack bars, cereals, and the like.
Background Of The Invention As humans age their mental faculties appear to lessen. This applies to humans in general and is not related to specific conditions such as Alzheimer's and other known-specific disease conditions affecting mental capacity. Memory is not as good as it once was.
Learning certain tasks can take a longer time. These types of mental changes are some times associated with or referred to as "old age".
Fairly recently this general area is known as cognitive function deterioration and in more generic terms as diminished mental capacity.
This deterioration of cognitive function in older humans can now be prevented, inhibited or treated with specific components.
These components can be administered in the diet or taken separately orally.
Summary Of The Invention In accordance with the invention there is a composition comprising an antioxidant or mixture thereof quantities sufficient to a. prevent or b. inhibit, or c. reverse deterioration of cognitive function, A further aspect is a method of preventing, inhibiting or reversing deterioration of cognitive function through the administration of this composition.
Detailed Description Of The Invention Humans can start having deterioration in cognitive function as early as about 50 but generally it can become noticeable at 60, or 70 years of age.
As used in this application, the components) that accomplish this are an antioxidant or mixture thereof. An antioxidant is a material that quenches a free radical. Examples of such materials are beta-carotene, selenium, coenzyme Q 10 (ubiquinone), lutein, tocotrienols, soy isoflavones, S-adenosylmethionine, glutathione, taurine, N-acetylcysteine, Vitamin E, Vitamin C, alpha-lipoic acid, 1-carnitine and the like. Vitamin E can be administered as a tocopherol or a mixture of tocopherols and various derivatives thereof such as esters like Vitamin E acetate, succinate, palmitate, and the like. The alpha form is preferable but beta, gamma and delta forms can be included. The d form is preferable but racemic mixtures are acceptable. The forms and derivatives will function in a Vitamin E like activity after ingestion. . Vitamin C can be administered as ascorbic acid and its various derivatives thereof such as calcium phosphate salts, cholesteryl salt, 2-monophosphate, and the like which will function in a vitamin C like activity after ingesting by the human.
They can be in any form such as liquid, semisolid, solid and heat stable form. Alpha-lipoic acid can be administered as alpha lipoic acid or as a lipoate derivative as in US Patent 5,621,117, racemic mixtures, salts, esters or amides thereof. L-carnitine and various derivatives of carnitine such as the salts such as the hydrochloride, fumarate and succinates, as well as acetylated carnitine, and the like can be used.
The quantities administered to the human are calculated as the active material, per se, that is measured as specific material. The minimum amounts employed should not bring about toxicity. Vitamin E minimum is about 50 or 100 or 150 mg/ day. Generally, no more than about 2,000 or desirably about 1,000 or about 750 mg/day can be employed. Vitamin C minimum quantities are generally about 150, about 200 or about 250 mg/day. Maximums generally do not exceed about 1,000 mg/day but can be lower, for example, about 900 or about 750 mg/ day. Alpha lipoic acid can be administered up to about or 20 mg/ kg body weight/ day. Minimums are about .5 or 1 mg/ kg body weight/ day. L-carnitine is administered in the same manner as alpha lipoic acid. Alpha lipoic acid and 1-carnitine can be administered at much higher levels but there is no substantially different efficacy observed.
Additional antioxidants and their quantities are given in mg/kg body weight/ day numbers.
Beta-carotene at least about 0.02 mg/kg body weight/day 1-15 ppm can be employed.
Selenium at about 0.02 mg/ kg body weight/ day up to 5 ppm can be employed.
Lutein at least about 5 ppm mg/kg body weight/day can be employed.
Tocotrienols at least about 0.5 mg/ kg 'body weight/ day can be employed.
Coenzyme Q 10 at least about 0.5 mg/ kg body weight/ day can be employed.
S-adenosylmethionine at least about 1.0 mg/ kg body weight/ day can be employed.
Taurine at least about 10 mg/kg body weight/day can be employed.
Soy isoflavones at least about 0.5 mg/kg body weight/day can. be used.
N-acetylcysteine at least about 1.0 mg/ kg/ body weight/ day can be used.
Glutathione at least about 1.0 g/kg body weight/day can be used.
Ginkgo Biloba at least 1.0 mg/kg body weight/day can be used.
The quantities can be administered in a typical "one a day"
dosage similar to a vitamin. It can be administered in tablet, capsule, caplet for example, or in a liquid carrier form all for ingestion by the human. Additionally, the daily dosage can be broken down into two, three, or four dosage unit forms for convenience or other reasons.
Additionally, it can be administered in a food such as snack bars, cereals, and the like.
Example 1 A supplement or food providing 750 mg vitamin E, 250 mg/
vitamin C, 200 mg lipoic acid and 400 mg of 1-carnitine is eaten by an adult human on a daily basis for 5 years starting at age 45. By the age of 50 no signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or health ears provider, are observed.
Example 2 An adult human having signs of mental deterioration, such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, as classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other ~ pertinent tests as diagnosed by themselves, a care-giver, or a health care provider, is provided a daily food or supplement providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of 1-carnitine on a daily basis for 1 year. After one year of dosing the above signs are significantly reduced.
vitamin C, 200 mg lipoic acid and 400 mg of 1-carnitine is eaten by an adult human on a daily basis for 5 years starting at age 45. By the age of 50 no signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or health ears provider, are observed.
Example 2 An adult human having signs of mental deterioration, such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, as classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other ~ pertinent tests as diagnosed by themselves, a care-giver, or a health care provider, is provided a daily food or supplement providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of 1-carnitine on a daily basis for 1 year. After one year of dosing the above signs are significantly reduced.
Example 3 An adult human having signs of mental deterioration such as disorientation, memory loss, learning impairment, or ability to cope independently with their environmental living situation, as classified by objective (or nonobjective) tests such as Folstein's Mini-mental State Exam (MME), Logical Memory and Visual Reproduction tests from the Wechsler Memory Scale (WMS), Katz' scale of activities of daily living, Lawton's scale of instrumental activities of daily living, Pfeiffer's mental status questionnaire, or other pertinent tests as diagnosed by themselves, a care-giver, or a health care provider, is provided a daily food or supplement providing 750 mg vitamin E, 250 mg/ vitamin C, 200 mg lipoic acid and 400 mg of 1-carnitine on a daily basis for 2 years. After 2 years of dosing the aforementioned signs have essentially disappeared.
Claims (10)
1. A composition comprising an antioxidant or mixture thereof in quantities sufficient to a. prevent, or b. inhibit, or c. reverse deterioration of cognitive function.
2. The composition in accordance with claim 1 wherein deterioration of cognitive function is prevented.
3. The composition in accordance with claim 1 wherein deterioration of cognitive function is inhibited.
4. The composition in accordance with claim 1 wherein deterioration of cognitive function is reversed.
5. The composition in accordance with claim 1 wherein Vitamin E
is at least about 50 mg/ day, Vitamin C is at least about 150 mg/day, 1-carnitine is at least about 0.5 mg/kg body weight/day, and alpha lipoic acid is at least about 0.5 mg/kg body weight/ day.
is at least about 50 mg/ day, Vitamin C is at least about 150 mg/day, 1-carnitine is at least about 0.5 mg/kg body weight/day, and alpha lipoic acid is at least about 0.5 mg/kg body weight/ day.
6. A method for preventing or inhibiting or reversing deterioration of cognitive function in a human which comprises administering a composition of claim 1 to said human.
7. The method in accordance with claim 6 wherein the human is in need of said administering.
8. The method in accordance with claim 6 wherein the deterioration of cognitive function is prevented.
9. The method in accordance with claim 6 wherein the deterioration of cognitive function is inhibited.
10. The method in accordance with claim 6 wherein the deterioration of cognitive function is reversed.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24451100P | 2000-10-31 | 2000-10-31 | |
| US60/244,511 | 2000-10-31 | ||
| US25344700P | 2000-11-28 | 2000-11-28 | |
| US25344600P | 2000-11-28 | 2000-11-28 | |
| US60/253,446 | 2000-11-28 | ||
| US60/253,447 | 2000-11-28 | ||
| US09/922,633 US20020052402A1 (en) | 2000-10-31 | 2001-08-06 | Composition and method |
| US09/922,633 | 2001-08-06 | ||
| PCT/US2001/048665 WO2002043666A2 (en) | 2000-10-31 | 2001-10-30 | Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2427470A1 true CA2427470A1 (en) | 2002-06-06 |
Family
ID=27500158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002427470A Abandoned CA2427470A1 (en) | 2000-10-31 | 2001-10-30 | Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1339404A2 (en) |
| JP (1) | JP2004514686A (en) |
| CN (1) | CN1477958A (en) |
| AU (1) | AU2002232616A1 (en) |
| CA (1) | CA2427470A1 (en) |
| WO (1) | WO2002043666A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005185188A (en) * | 2003-12-25 | 2005-07-14 | Nichirei Corp | Composition containing treated product of acerola and l-carnitine |
| AU2005211165B8 (en) * | 2004-01-28 | 2011-07-14 | Nestec S.A. | Nutritional composition for improving skin condition and preventing skin diseases |
| CA2588708C (en) * | 2004-11-24 | 2014-05-27 | Hill's Pet Nutrition, Inc. | Use of lipoic acid to improve immune response by increased natural killer cell activity |
| WO2006058278A2 (en) * | 2004-11-24 | 2006-06-01 | Hill's Pet Nutrition, Inc. | Methods for improving liver clearance of xenobiotic substances in an animal |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| EP1928453B1 (en) * | 2005-08-17 | 2017-10-18 | Hill's Pet Nutrition, Inc. | Compositions and their use for the prevention and treatment of kidney disease |
| CN1895671B (en) * | 2005-12-08 | 2012-11-28 | 淮北辉克药业有限公司 | Compound preparation for treating viral liver disease |
| CN101045048B (en) * | 2006-03-27 | 2011-05-18 | 中国科学院上海生命科学研究院 | Application of chondriosome nutrient composition |
| US20100076091A1 (en) * | 2007-02-14 | 2010-03-25 | Tohoku University | Composition and method for suppressing lipooxidation of erythrocyte |
| CN102469807A (en) * | 2009-07-14 | 2012-05-23 | 希尔氏宠物营养品公司 | Pet food compositions including a sustained-release lipoic acid and methods of manufacture and use thereof |
| JP2014532032A (en) | 2011-04-05 | 2014-12-04 | ロンザ・リミテッド | Use of L-carnitine, its salts and derivatives for reducing or preventing fatigue and for improving cognitive function |
| EP2508179A1 (en) | 2011-04-05 | 2012-10-10 | Lonza Ltd. | Use of L-Carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function |
| NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06199690A (en) * | 1992-03-06 | 1994-07-19 | Yunie:Kk | Agent for promoting cerebral metabolism and improving cerebral function |
| DE4343592C2 (en) * | 1993-12-21 | 1998-04-16 | Asta Medica Ag | Use of R - (+) - alpha-lipoic acid and its metabolites in the form of the free acid or as salts or esters or amides for the treatment of glucose metabolic disorders in the central nervous system |
| FR2721516B1 (en) * | 1994-06-27 | 1996-09-13 | Inst Rech Biolog Sa | New uses of a complex based on brain phospholipids in therapy and in food. |
| US5977162A (en) * | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
| IT1302307B1 (en) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL |
| DE60004797T2 (en) * | 1999-03-16 | 2004-06-17 | Merck Patent Gmbh | MEDICINAL PRODUCTS WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES CONTAINING ISOQUERCETINE AND ASCORBIC ACID |
| AU3913800A (en) * | 1999-03-26 | 2000-10-16 | Lipogenics, Inc. | Novel antioxidant formulations and methods for using them |
| DE19920316A1 (en) * | 1999-05-03 | 1999-12-09 | Heinz Kiefer | Antioxidant medicament containing vitamins and trace elements, useful e.g. for maintaining cellular function and preventing cancer |
| WO2000076492A1 (en) * | 1999-06-15 | 2000-12-21 | Nutri-Logics, Inc. | Nutrient formulations for disease reduction, and related treatment and component screening methods |
| WO2001032168A1 (en) * | 1999-11-03 | 2001-05-10 | Juvenon, Inc. | Method of treating benign forgetfulness |
| US20010043983A1 (en) * | 2000-01-25 | 2001-11-22 | Hamilton Nathan D. | Nutritional supplements for aged pets |
| HU227182B1 (en) * | 2000-03-06 | 2010-09-28 | Andras Javor | Lecitin-ascorbic acid combination |
-
2001
- 2001-10-30 WO PCT/US2001/048665 patent/WO2002043666A2/en not_active Application Discontinuation
- 2001-10-30 CN CNA018181880A patent/CN1477958A/en active Pending
- 2001-10-30 CA CA002427470A patent/CA2427470A1/en not_active Abandoned
- 2001-10-30 EP EP01992146A patent/EP1339404A2/en not_active Withdrawn
- 2001-10-30 JP JP2002545645A patent/JP2004514686A/en active Pending
- 2001-10-30 AU AU2002232616A patent/AU2002232616A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1339404A2 (en) | 2003-09-03 |
| WO2002043666A3 (en) | 2003-01-30 |
| AU2002232616A1 (en) | 2002-06-11 |
| CN1477958A (en) | 2004-02-25 |
| WO2002043666A2 (en) | 2002-06-06 |
| JP2004514686A (en) | 2004-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6716451B1 (en) | Formulation and delivery method to enhance antioxidant potency of vitamin E | |
| US9278109B2 (en) | Compositions and methods for the prevention of cardiovascular disease | |
| US6203818B1 (en) | Nutritional supplement for cardiovascular health | |
| US7410659B2 (en) | Methods for the treatment of peripheral neural and vascular ailments | |
| US20020076470A1 (en) | Composition and method | |
| CA2427470A1 (en) | Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function | |
| US20020172721A1 (en) | Vitamin formulation for cardiovascular health | |
| BRPI0620210A2 (en) | composition and processes for inhibiting the progression of macular degeneration and promoting healthy vision | |
| ES2546055T3 (en) | Nutritional supplements for individuals 50 years or older to improve vitality, immunity, eye and bone health | |
| US20080181972A1 (en) | Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health | |
| WO2000057876A1 (en) | Novel antioxidant formulations and methods for using them | |
| JP2008214338A (en) | Agent for ameliorating lowering of high-order brain function and agent for ameliorating lowering of short-term memory | |
| US20020076469A1 (en) | Composition and method | |
| US20020052402A1 (en) | Composition and method | |
| CA2746902C (en) | A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
| US7399755B2 (en) | Formulations comprising multiple dietary and endogenously made antioxidants and B-vitamins and use of same | |
| Subasree | Role of vitamin C and vitamin E in health and disease | |
| ZA200303749B (en) | Compositions containing an antioxidant such as alpha lipoic acid, carnitine, Vitamin C or Vitamin E for preventing or inhibiting loss of cognitive function. | |
| US6358997B1 (en) | Tocopherol and tocotrienol compositions | |
| EP1036510A2 (en) | Vitamin formulation for cardiovascular health | |
| JP2005170834A (en) | Skin ameliorating preparation | |
| US6207187B1 (en) | Compositions based on tocopherols | |
| US20130196934A1 (en) | Composition for perinatal and neonatal stroke | |
| WO1996019218A1 (en) | Tocopherol and tocotrienol compositions | |
| JP2006232815A (en) | Medicine composition for increasing blood coq10 amount |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |